Inspec

Inspec R&D / Revenue

The R&D to Revenue Ratio of Inspec (6656.T) as of Nov 13, 2026 is 10.33 %. In the previous year, R&D to Revenue Ratio was 16.04 % — a change of -35.56% (lower).

R&D / Revenue

10.33 %

YoY

-35.56%

Last updated:

R&D to Revenue Ratio of Inspec is 2026 10.33 % . R&D to Revenue Ratio of Inspec was 2025 16.04 % . It decreases by -35.56% lower compared to the previous year.

The Inspec R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2019
4.53 JPY
Jan 1, 2020
7.76 JPY
Jan 1, 2021
14.09 JPY
Jan 1, 2022
12.89 JPY
Jan 1, 2023
12.45 JPY
Jan 1, 2024
25.48 JPY
Jan 1, 2025
16.04 JPY
Jan 1, 2026
10.33 JPY
The Inspec R&D / Revenue history
YEARR&D / RevenueYoY
10.33 %-35.56%
16.04 %-37.06%
25.48 %+104.68%
12.45 %-3.42%
12.89 %-8.56%
14.09 %+81.58%
7.76 %+71.35%
4.53 %-33.40%
6.80 %+44.10%
4.72 %-0.44%
4.74 %-32.22%
6.99 %-20.63%
8.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inspec Stock analysis

What does Inspec do? inspec Inc. generates revenue through three primary segments. The Semiconductor Package Substrates and Precision Substrate Inspection Equipment segment sells appearance inspection equipment for semiconductor package substrates and precision printed circuit boards used in smartphones, tablets, PCs, and wearable terminals. The Precision Substrate Manufacturing Equipment segment provides photoplotters, inkjet printers, and direct imaging devices along with maintenance services for printed circuit boards. The Digital Pathology Related Equipment segment develops and sells medical image processing systems, specifically whole slide imaging (WSI) for digital pathology applications. Customers include manufacturers of advanced digital devices requiring semiconductor inspection, PCB producers needing photoplotters and imaging devices, and healthcare providers utilizing whole slide imaging systems for pathology diagnostics. The company's products target the semiconductor, electronics manufacturing, and medical imaging sectors with specific applications in device assembly, PCB production, and medical diagnostics. inspec Inc. focuses on equipment for semiconductor package substrates, precision substrates, and digital pathology, serving clients in the electronics and healthcare industries. The firm's inspection and imaging solutions are tailored to meet the quality control needs of high-tech manufacturing and medical diagnostics, with no mention of additional revenue streams beyond these three segments. Inspec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inspec stock

R&D to Revenue Ratio of Inspec is 10.33 % in 2026.

R&D to Revenue Ratio of Inspec changed from 16.04 % to 10.33 %, representing a -35.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Inspec since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Inspec with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Inspec

All Key Metrics — Inspec